20-Aug-2026
Tonix Pharma Names CEO Seth Lederman Interim CMO
TipRanks (Tue, 18-Aug 4:36 PM ET)
TipRanks (Tue, 18-Aug 6:01 AM ET)
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Globe Newswire (Mon, 10-Aug 7:00 AM ET)
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
Globe Newswire (Mon, 3-Aug 7:00 AM ET)
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Globe Newswire (Mon, 27-Jul 7:00 AM ET)
Globe Newswire (Wed, 15-Jul 9:05 AM ET)
Tonix Pharmaceuticals Expands TONMYA Coverage to 145 Million Lives with Major Medicare Agreement
Market Chameleon (Mon, 13-Jul 4:30 AM ET)
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA
Globe Newswire (Mon, 13-Jul 7:00 AM ET)
Globe Newswire (Mon, 29-Jun 7:25 AM ET)
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Tonix Pharmaceuticals Holding Corp. trades on the NASDAQ stock market under the symbol TNXP.
As of August 20, 2026, TNXP stock price declined to $12.39 with 355,256 million shares trading.
TNXP has a beta of 1.26, meaning it tends to be more sensitive to market movements. TNXP has a correlation of 0.04 to the broad based SPY ETF.
TNXP has a market cap of $212.50 million. This is considered a Small Cap stock.
Last quarter Tonix Pharmaceuticals Holding Corp. reported $14 million in Revenue and -$2.44 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.20.
In the last 3 years, TNXP traded as high as $3,232.00 and as low as $6.76.
The top ETF exchange traded funds that TNXP belongs to (by Net Assets): IWM, VTI, FESM, VXF, IWN.
TNXP has underperformed the market in the last year with a return of -65.6%, while the SPY ETF gained +20.7%. In the last 3 month period, TNXP fell short of the market, returning -14.6%, while SPY returned +3.1%. However, in the most recent 2 weeks TNXP has outperformed the stock market by returning +6.4%, while SPY returned -0.8%.
TNXP support price is $12.14 and resistance is $13.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TNXP shares will trade within this expected range on the day.